HERZLIYA, Israel and CALGARY, Alberta — November 25, 2025 — Leads & Copy —
Innocan Pharma Corporation (CSE: INNO, FSE: IP40, OTCQB: INNPD) has announced the publication of a research article in Frontiers in Pharmacology, showcasing positive results from a study on the use of Liposomal-synthetic-cannabidiol (LPT-CBD) for pain relief. The article, titled “Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats,” details findings from repeated subcutaneous injections in two goats suffering from chronic and disabling painful conditions. The peer reviewed esteemed journal can be found at https://doi.org/10.3389/fphar.2025.1689226.
The study involved administering Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) via subcutaneous injections every six weeks over 10 months to the goats. Researchers monitored CBD and metabolite plasma concentrations, along with hematological and biochemical profiles, through serial blood sampling before and after each injection. Caregivers assessed efficacy weekly using a quality of life (QoL) scoring system, while also monitoring for any adverse effects.
Key findings from the study include:
- Sustained CBD plasma concentrations were maintained through repeated LPT-CBD injections, showing a slow-release pharmacokinetic profile.
- The drug was well-tolerated, with no adverse events recorded during the study.
- Unlike repeated oral CBD consumption in humans, LPT-CBD injections did not cause elevated liver enzymes.
- Consistent pain relief, improved mobility, and enhanced quality of life were observed throughout the 10-month study period.
Researchers said the results provide clinically relevant information, highlighting the practicality of LPT-CBD injections every six weeks, the absence of adverse effects, and the maintenance of long-term CBD plasma concentrations. The study also indicated that LPT-CBD shows promising trends in pain management and overall well-being improvement.
Professor Chezy Barenholz, Head of the Advisory Board, noted the sustained beneficial effects of LPT-CBD over 10 months, stating that the study offers encouraging evidence for the use of repeated monthly administrations to treat chronic conditions.
Dr. Eyal Kalo, Vice President of Research and Development, said the research supports a favorable long-term safety profile for LPT-CBD, as it did not elevate liver enzymes, unlike repeated oral CBD intake, which has been linked to potential liver injury.
For Innocan Pharma Corporation contact Iris Bincovich, CEO, at +1 5162104025, +972-54-3012842, +442037699377, or via email at info@innocanpharma.com.
Source: Innocan Pharma Corporation
